- Home
- MCRB vs MRCC Comparison
MCRB vs MRCC Comparison
Compare MCRB & MRCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- MRCC
- Stock Information
- Founded
- MCRB 2010
- MRCC 2011
- Country
- MCRB United States
- MRCC United States
- Employees
- MCRB N/A
- MRCC N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- MRCC Investment Managers
- Sector
- MCRB Health Care
- MRCC Finance
- Exchange
- MCRB Nasdaq
- MRCC Nasdaq
- Market Cap
- MCRB 144.6M
- MRCC 151.7M
- IPO Year
- MCRB 2015
- MRCC 2012
- Fundamental
- Price
- MCRB $17.75
- MRCC $6.86
- Analyst Decision
- MCRB Hold
- MRCC Hold
- Analyst Count
- MCRB 4
- MRCC 1
- Target Price
- MCRB $14.33
- MRCC $8.00
- AVG Volume (30 Days)
- MCRB 101.5K
- MRCC 69.3K
- Earning Date
- MCRB 11-12-2025
- MRCC 11-11-2025
- Dividend Yield
- MCRB N/A
- MRCC 14.49%
- EPS Growth
- MCRB N/A
- MRCC N/A
- EPS
- MCRB 10.22
- MRCC 0.09
- Revenue
- MCRB N/A
- MRCC $51,229,000.00
- Revenue This Year
- MCRB N/A
- MRCC N/A
- Revenue Next Year
- MCRB N/A
- MRCC N/A
- P/E Ratio
- MCRB $1.74
- MRCC $78.11
- Revenue Growth
- MCRB N/A
- MRCC N/A
- 52 Week Low
- MCRB $6.53
- MRCC $5.96
- 52 Week High
- MCRB $24.67
- MRCC $8.85
- Technical
- Relative Strength Index (RSI)
- MCRB 42.40
- MRCC 40.65
- Support Level
- MCRB $17.63
- MRCC $6.78
- Resistance Level
- MCRB $19.30
- MRCC $7.03
- Average True Range (ATR)
- MCRB 1.12
- MRCC 0.15
- MACD
- MCRB -0.29
- MRCC -0.01
- Stochastic Oscillator
- MCRB 5.42
- MRCC 15.62
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.